The board of directors of Hansoh Pharmaceutical Group Company Limited announced that " HS-10383 tablets ", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd., a subsidiary of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of refractory or unexplained chronic cough. The specific indication will be determined after the completion of clinical research.